Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 28 Jun 2018
At a glance
- Drugs POL 6014 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Santhera Pharmaceuticals
- 19 Jun 2018 Status changed from planning to recruiting.
- 15 Feb 2018 According to a Santhera Pharmaceuticals media release, this trial is planned to initiate in the second half of 2018.
- 12 Apr 2017 New trial record